O

Omeros Corp
D

OMER

3.21000
USD
0.12
(3.88%)
مغلق
حجم التداول
12,207
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
188,082,609
أصول ذات صلة
A
ARWR
-0.120
(-0.71%)
16.790 USD
F
FATE
0.02000
(1.80%)
1.13000 USD
M
MDGL
-2.26
(-0.75%)
298.20 USD
M
MRSN
0.01280
(4.56%)
0.29380 USD
M
MRUS
0.510
(0.96%)
53.850 USD
S
SRPT
0.010
(0.06%)
18.200 USD
المزيد
الأخبار المقالات

العنوان: Omeros Corp

القطاع: Healthcare
الصناعة: Biotechnology
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.